Bevetex Injection 0.91ml

Bevetex Injection 0.91ml may interact with other medicines, such as:

• Antitubercular medicines (e.g., rifampicin): Decrease paclitaxel levels by inducing liver enzymes, which may reduce its effectiveness in controlling cancer. Close monitoring and dose adjustment may be needed.
• Antiepileptic medicines (e.g., phenytoin, carbamazepine, phenobarbital): Decrease the effectiveness of paclitaxel by increasing its metabolism in the liver. This may reduce its anticancer effect, and dose adjustment or monitoring may be required.
• CYP3A4 and CYP2C8 inhibitors (e.g., ketoconazole, erythromycin, fluoxetine, gemfibrozil, trimethoprim): Increase paclitaxel levels in the body by slowing its breakdown. This may increase the risk of side effects such as bone marrow suppression and nerve toxicity.
• CYP3A4 and CYP2C8 inducers (e.g., carbamazepine, efavirenz, nevirapine, St. John’s wort): Decrease paclitaxel levels by increasing its metabolism, which may reduce its effectiveness. Monitoring and dose adjustment may be required.
• Other anticancer medicines (e.g., cisplatin, doxorubicin, trastuzumab): Increase toxicity depending on the sequence and combination. For example, giving cisplatin before paclitaxel may increase bone marrow suppression, and combination with doxorubicin may increase heart-related side effects. Careful scheduling and monitoring are required.
• CNS depressants (e.g., diazepam, lorazepam): Increase sedative effects due to the alcohol content in this medicine, leading to dizziness, drowsiness, and reduced alertness.

Use Bevetex Injection 0.91ml with caution if you have:

• Infections: This medicine may worsen existing infections due to its effect on lowering white blood cell counts. Your doctor may monitor you closely and may delay treatment if you have an active infection.
• Conduction disorders (cardiac arrhythmias): Bevetex Injection 0.91ml may affect heart rhythm and worsen existing conduction problems. Your doctor may monitor your heart function during treatment if needed.
• Hepatic impairment (liver disease): Reduced liver function may increase the levels of this medicine in the body, raising the risk of side effects. Your doctor may adjust the dose and check liver function regularly.
• Myelosuppression (low blood counts): This medicine can further lower blood cell counts, increasing the risk of infections, anaemia, and bleeding. Your doctor may perform regular blood tests and adjust treatment based on results.
• Peripheral neuropathy: Bevetex Injection 0.91ml may worsen nerve-related symptoms such as numbness, tingling, or weakness. Your doctor may reduce the dose or modify treatment if symptoms become severe.

The dose of Bevetex Injection 0.91ml is determined by your oncologist based on your body surface area (BSA), type and stage of cancer, previous chemotherapy, and overall health. It is administered intravenously in a clinical setting. The frequency and duration of treatment are tailored to the chemotherapy protocol. It is essential to follow the exact prescribed schedule and never adjust the dose on your own, as under- or over-dosing can affect treatment effectiveness or increase side effects.

Overdose is unlikely, as this medicine is administered under medical supervision in a controlled setting. However, excessive exposure may increase the risk of serious side effects such as severe bone marrow suppression, nerve damage, or inflammation of the mouth. If overdose is suspected, immediate medical attention is required.

If you miss a scheduled treatment session, consult your doctor as soon as possible to reschedule. Do not attempt to adjust or skip doses on your own, as maintaining the treatment schedule is important for effectiveness.